Coronavirus (COVID-19) News
Filter News
Found 2,375 articles
-
Vela Diagnostics Supports COVID-19 Surveillance Efforts in Kenya
8/3/2022
Vela Diagnostics has announced its appointment by the National Public Health Laboratory of Kenya as their supplier for SARS-CoV-2 genotyping tests, with funding from The Global Fund.
-
According to two recent studies, 10 to 30% of people with COVID-19 reported at least one persistent symptom up to six months after infection, which qualifies as Long COVID. -
Axcella Announces Highly Promising Results from Phase 2a Placebo Controlled Clinical Trial for Long COVID
8/2/2022
Axcella Therapeutics reported topline results from the Phase 2a randomized, double-blind, placebo-controlled investigation to evaluate the efficacy and safety of AXA1125 in patients with fatigue related to Long COVID.
-
SyneuRx Announces Final Results of Phase 2 Clinical Trial of COVID-19 Oral Antiviral Candidate Pentarlandir® (SNB01)
8/1/2022
SyneuRx™ International, a global biotech company focused on the development of new classes of drugs for COVID-19 and multiple major central nervous system disorders, announced results from its phase 2 clinical trial evaluating the efficacy and safety of SNB01, a novel COVID-19 oral antiviral candidate.
-
GreenLight Biosciences and Samsung Biologics complete first commercial-scale engineering run for mRNA Covid-19 vaccine
8/1/2022
GreenLight Biosciences and Samsung Biologics announced the successful completion of the first commercial-scale engineering run for the companies’ mRNA production partnership.
-
Persistent Loss of Smell Due to Covid-19 Closely Connected to Long-lasting Cognitive Problems
7/31/2022
New insights into factors that may predict, increase or protect against the impact of COVID-19 and the pandemic on memory and thinking skills were revealed by multiple studies reported at the Alzheimer's Association International Conference® 2022 in San Diego and virtually.
-
COVID-19 has been remarkably profitable for Pfizer over the last year-and-a-half. The company’s revenue jumped by 47% to $27.7 billion compared to the same period in 2021.
-
“The applications for mRNA are quite broad, because, basically, you are giving information to a cell to make any protein you want," CureVac CFO Pierre Kemula told BioSpace.
-
NIH, GreenLight Biosciences to collaborate on COVID-19 vaccine development for new variants
7/29/2022
GreenLight Biosciences has announced a collaboration with the National Institutes of Health to develop COVID-19 vaccines that are more broadly protective against new variants and with longer-lasting effects.
-
As part of 'Operation Nasal Vaccine' to counter COVID-19 spread, ACM-001 booster vaccine administered to first subject in phase 1 safety and immunogenicity trial
7/29/2022
ACM Biolabs announced that the first subject has been dosed in the first–in–human Phase 1 trial of its clinical candidate vaccine, ACM-001, a 2nd generation adjuvanted SARS-CoV-2 spike protein vaccine with broad protection against variants of concerns, including delta and omicron demonstrated in a variety of preclinical studies.
-
Pfizer and BioNTech initiated a Phase II trial of an enhanced COVID-19 vaccine while fending off lawsuits against CureVac and Alnylam over their technology.
-
SARS-CoV-2 typically enters the body via the nose or mouth. Because of this, many think a nasal spray vaccine would do a better job of preventing COVID-19 infection and cutting transmission than an injection.
-
Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design
7/27/2022
Pfizer Inc. and BioNTech SE announced that the companies have initiated a randomized, active-controlled, observer-blind Phase 2 study to evaluate the safety, tolerability, and immune response of an enhanced COVID-19 mRNA-based vaccine candidate at a 30 µg dose level.
-
Researchers at the Institut Pasteur in Paris, France have found that the COVID-19 virus enters the brain through nanotubes to cause debilitating neurologic symptoms.
-
Here’s a look at the latest Long COVID research and the reemergence of a therapy whose efficacy has yet to be proven.
-
WHO declared the monkeypox outbreak a “public health emergency of international concern [PHEIC].” As COVID-19 wanes, Tonix, SIGA, Emergent Bio and others are now targeting monkeypox.
-
Two Clinical Studies to Treat Mild-to-Moderate COVID-19 at Home Reveal Value of Exscalate, Dompé's AI Platform for Drug Design
7/26/2022
Dompé farmaceutici S.p.A announced positive results from two studies demonstrating that treatment with oral raloxifene, a selective estrogen receptor modulator with a proven safety profile, may be effective against SARS-CoV-2, including its clinically relevant variants.
-
Here’s a look at global biopharma company news stories including Rona Therapeutics, Genuine Bio and NEOsphere Bio. -
UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) Supports Expedited Review of Marketing Authorization Application for Sabizabulin Treatment in Hospitalized COVID-19 Patients
7/25/2022
Veru Inc. announced that the United Kingdom’s Medicines and Healthcare Products Regulatory Agency considers that the currently available safety and efficacy data will support an expedited review of the marketing authorization application for the Company’s sabizabulin treatment in hospitalized COVID-19 patients at high risk for Acute Respiratory Distress Syndrome when the application is submitted.
-
Vaxxinity CEO Mei Mei Hu Speaking at White House Summit on the Future of COVID-19 Vaccines
7/25/2022
Vaxxinity, Inc. Chief Executive Officer Mei Mei Hu will participate as a speaker at the White House Summit on the Future of COVID-19 Vaccines.